|
KMID : 1001020140120020059
|
|
Journal of Urologic Oncology
2014 Volume.12 No. 2 p.59 ~ p.64
|
|
|
The Role of Immunotherapy in the Era of TKI with Metastatic Renal Cell Carcinoma
|
|
Lee Ki-Soo
Kim Tae-Hyo
|
|
|
Abstract
|
|
|
|
Treatment of metastatic renal cell cancer (mRCC) is rapidly evolving since evidence concerning efficacy of novel molecular targeted drugs recently became available. But, Tyrosine kinase inhibitors achieve objective response or disease stabilization in a higher proportion of patients, but neither cure nor significant survival advantage has been shown for these agents. The role of conventional immunotherapy is still supported to the some patients in some medical centers. we will show the currently approved options available for these disease processes, including the newer agents and selected combinatorial approaches under investigation, and we attempt to identify the role of high-dose IL-2 in the context of current clinical practice. This paper provides a critical overview of the current and future role of cytokine-based immunotherapy in mRCC in light of these new developments.
|
|
|
KEYWORD
|
|
|
Renal cell carcinoma, Metastasis, Immunotherphy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|